Scribe Therapeutics, Inc. — Form S-1

Scribe Therapeutics, a clinical-stage biotechnology company, is conducting an IPO to develop in vivo CRISPR-based genetic medicines targeting cardiovascular and metabolic diseases. Founded in 2017 with co-founder Dr. Jennifer Doudna (Nobel laureate), the company has raised ~$150M in private equity and ~$180M in collaboration payments (Sanofi, Eli Lilly). As of March 31, 2026, Scribe had $49.7M in cash/investments, accumulated deficit of $175.1M, net loss of $17.3M in Q1 2026, and management disclosed substantial doubt about going-concern status. Lead program STX-1150 initiated first-in-human trial in Australia with 64 patients; initial data expected H1 2027. Two additional programs (STX-1200, STX-1400) targeting Lp(a) and triglycerides in preclinical stage with CIRM funding of ~$25.7M. Company is non-accelerated filer and emerging growth company with reduced disclosure obligations.